Camostat mesylate therapy in critically ill patients with COVID-19 pneumonia

Intensive Care Med. 2021 Jun;47(6):707-709. doi: 10.1007/s00134-021-06395-1. Epub 2021 Apr 12.

Authors

Yasser Sakr¹, Hatim Bensasi², Ahmed Taha³, Michael Bauer⁴, Khaled Ismail²; the UAE-Jena Research Group

Collaborators

the UAE-Jena Research Group:
Ghazala Belhaj, Khaled M Afet, Dnyanwshwar Munde, David Monk, Samuel Buschbeck

Affiliations

¹ Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Am Klinikum 1, 07743, Jena, Germany. yasser.sakr@med.uni-jena.de.
² Department of Anesthesiology and Critical Care Medicine, Al Ain Hospital, SEHA, Abu Dhabi, UAE.
³ Department of Critical Care, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE.
⁴ Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Am Klinikum 1, 07743, Jena, Germany.

No abstract available

Publication types

Letter

MeSH terms

COVID-19*
Critical Illness
Esters
Guanidines
Humans
Mesylates
SARS-CoV-2

Substances

Esters
Guanidines
Mesylates
camostat